Who owns Syndax Pharmaceuticals Inc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SNDX from SEC Form 13F filings across 241 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 241 institutions disclosed 108.0M shares of Syndax Pharmaceuticals Inc worth $2.36B — about 121.3% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
241
13F holders
$2.36B
value, 2026 filers
121.3%
of shares outstanding (108.0M sh)
38
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of SNDX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.0M | $197.2M | 0.0% | 10.1% | +9.3% |
| 2 | Kynam Capital Management, LP | 8.1M | $176.0M | 9.7% | 9% | 0.0% |
| 3 | GOLDMAN SACHS GROUP INC | 5.9M | $128.1M | 0.0% | 6.6% | +17.3% |
| 4 | STATE STREET CORP | 5.7M | $123.7M | 0.0% | 6.4% | +27.7% |
| 5 | BANK OF AMERICA CORP /DE/ | 4.0M | $88.4M | 0.0% | 4.5% | -4.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $85.9M | 0.0% | 4.4% | +2.8% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.8M | $82.6M | 0.9% | 4.2% | 0.0% |
| 8 | Eversept Partners, LP | 2.8M | $61.2M | 3.2% | 3.1% | -3.0% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $56.5M | 0.0% | 2.9% | +19.8% |
| 10 | Hood River Capital Management LLC | 2.6M | $56.1M | 0.4% | 2.9% | +8.9% |
| 11 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.5M | $54.6M | 5.6% | 2.8% | 0.0% |
| 12 | FRANKLIN RESOURCES INC | 2.3M | $50.0M | 0.0% | 2.6% | +6.3% |
| 13 | MILLENNIUM MANAGEMENT LLC | 2.1M | $44.9M | 0.0% | 2.3% | +929.4% |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.9M | $42.0M | 0.0% | 2.2% | +10.6% |
| 15 | UBS Group AG | 1.9M | $41.4M | 0.0% | 2.1% | +64.2% |
| 16 | Elmind Capital, LP | 1.9M | $40.6M | 10.2% | 2.1% | 0.0% |
| 17 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.8M | $39.1M | 0.0% | 2% | +3.3% |
| 18 | Candriam S.C.A. | 1.7M | $37.0M | 0.2% | 1.9% | +83.3% |
| 19 | Soleus Capital Management, L.P. | 1.6M | $35.6M | 1.2% | 1.8% | -5.7% |
| 20 | TWO SIGMA INVESTMENTS, LP | 1.6M | $34.5M | 0.0% | 1.8% | -0.1% |
| 21 | ORBIMED ADVISORS LLC | 1.5M | $33.7M | 0.6% | 1.7% | +60.2% |
| 22 | Nuveen, LLC | 1.4M | $29.8M | 0.0% | 1.5% | -8.7% |
| 23 | MPM BIOIMPACT LLC | 1.3M | $29.2M | 1.8% | 1.5% | -0.5% |
| 24 | Aisling Capital Management LP | 1.3M | $28.8M | 6.1% | 1.5% | 0.0% |
| 25 | Woodline Partners LP | 1.3M | $27.3M | 0.1% | 1.4% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.